Immuneering reported a significant improvement in its cash position following financing efforts, ending the year with $217 million. The company achieved positive Phase 2a clinical data in pancreatic cancer and secured regulatory alignment for its upcoming Phase 3 trial, while narrowing its quarterly net loss compared to the prior year.

Immuneering ended Q3 2025 with strong financial backing from recent funding and reported continued investment in R&D for its lead oncology programs, despite posting a net loss.

Immuneering reported a net loss of $15.0 million for Q1 2025, compared to $14.3 million in Q1 2024. The company's cash and cash equivalents stood at $35.9 million, with a cash runway extended into 2026. Clinical progress for IMM-1-104 in pancreatic cancer showed promising results, including a patient passing the 13-month mark on monotherapy.

Immuneering reported a larger net loss in Q4 2024 due to increased R&D expenses as the company advanced its IMM-1-104 clinical program. The company ended the quarter with $36.1 million in cash and cash equivalents and extended its cash runway into 2026.